Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 5/20 | 0.38 |
| ▸ | RAB9A | P51151 | 5/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.37 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 4/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | PARP1 | P09874 | 1/20 | 0.34 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.34 |
| ▸ | NOS3 | P29474 | 1/20 | 0.34 |
| ▸ | NOS1 | P29475 | 1/20 | 0.34 |
| ▸ | NOS2 | P35228 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | HTR5A | P47898 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2616783 | 0.88 | NPY5R (0.38) | NPC1RAB9AHPGDMAPTSMN1; SMN2 | |
| SCHEMBL2616770 | 0.83 | PDE3B (0.41) | NPC1RAB9AHPGDCYP19A1CYP11B2 | |
| SCHEMBL10354061 | 0.81 | KMT2A (0.38) | NPC1RAB9AMAPTSMN1; SMN2HTT | |
| SCHEMBL17751177 | 0.74 | CSNK2A1 (0.37) | NPC1RAB9AHPGDMAPTSMN1; SMN2 | |
| SCHEMBL30681225 | 0.74 | NOS3 (0.57) | NPC1RAB9AHPGDCYP19A1CYP11B2 | |
| SCHEMBL2230501 | 0.74 | NOS3 (0.57) | NPC1RAB9AHPGDCYP19A1CYP11B2 | |
| SCHEMBL7495994 | 0.72 | PARP10 (0.35) | NPC1RAB9AHPGDCYP19A1CYP11B2 | |
| SCHEMBL2616781 | 0.72 | PDE3B (0.39) | NPC1RAB9AHPGDMAPTSMN1; SMN2 | |
| SCHEMBL24454359 | 0.71 | L3MBTL1 (0.44) | NPC1RAB9AHPGDMAPTSMN1; SMN2 | |
| SCHEMBL7934329 | 0.69 | PARP10 (0.33) | NPC1RAB9AHPGDCYP19A1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11806343-B2 | Inhibitors of DUX4 induction for regulation of muscle function | SONIC MASTER LIMITED (VG) | 2023-11-07 | — | — | US | disclosed |
| US-11806343-B2 | Inhibitors of DUX4 induction for regulation of muscle function | SONIC MASTER LIMITED (VG) | 2023-11-07 | — | — | US | disclosed |
| US-20210361641-A1 | Inhibitors of DUX4 Induction for Regulation of Muscle Function | GENEA BIOCELLS US, INC. | 2021-11-25 | — | — | US | disclosed |
| US-11065243-B2 | Inhibitors of DUX4 induction for regulation of muscle function | SONIC MASTER LIMITED (VG) | 2021-07-20 | — | — | US | disclosed |
| US-20200330452-A1 | Inhibitors of Dux4 Induction for Regulation of Muscle Function | SONIC MASTER LIMITED (VG) | 2020-10-22 | — | — | US | disclosed |
| US-8586565-B2 | Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases | DECIPHERA PHARMACEUTICALS, LLC (US) | 2013-11-19 | — | — | US | disclosed |
| US-20120225057-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF MYELOPROLIFERATIVE DISEASES AND OTHER PROLIFERATIVE DISEASES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2012-09-06 | — | — | US | disclosed |
| US-8163756-B2 | For example,1-(3-t-butyl-1- (1,2,3,4-tetrahydro- isoquinolin-6-yl)-1H- pyrazol-5-yl)-3-(3- cyanophenyl)urea; for treatment of mammalian cancers and inflammatory diseases including rheumatoid arthritis, retinopathies | DECIPHERA PHARMACEUTICALS, LLC (US) | 2012-04-24 | — | — | US | disclosed |
| US-20110136760-A1 | Kinase Inhibitors Useful for the Treatment of Myleoproliferative Diseases and other Proliferative Diseases | DECIPHERA PHARMACEUTICALS, LLC | 2011-06-09 | — | — | US | disclosed |
| US-7790756-B2 | Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases | DECIPHERA PHARMACEUTICALS, LLC (US) | 2010-09-07 | — | — | US | disclosed |
| US-20080113967-A1 | ENZYME MODULATORS AND TREATMENTS | DECIPHERA PHARMACEUTICALS, LLC (US) | 2008-05-15 | — | — | US | disclosed |
| US-20080090856-A1 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF MYLEOPROLIFERATIVE DISEASES AND OTHER PROLIFERATIVE DISEASES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2008-04-17 | — | — | US | disclosed |
| US-20070078121-A1 | Enzyme modulators and treatments | DECIPHERA PHARMACEUTICALS, LLC | 2007-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120225057-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF MYELOPROLIFERATIVE DISEASES AND OTHER PROLIFERATIVE DISEASES | ABL1, MCL1, ABL2 | NPC1 3601/4885RAB9A 1325/4885HPGD 2917/4885 |
| US-20080090856-A1 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF MYLEOPROLIFERATIVE DISEASES AND OTHER PROLIFERATIVE DISEASES | MYLK3, MYLK, CDK3 | NPC1 3414/4885RAB9A 1929/4885HPGD 2057/4885 |
| US-11806343-B2 | Inhibitors of DUX4 induction for regulation of muscle function | MUSK, MERTK, PRKDC | NPC1 4817/4885RAB9A 2989/4885HPGD 3740/4885 |
| US-20200330452-A1 | Inhibitors of Dux4 Induction for Regulation of Muscle Function | MUSK, MERTK, PRKDC | NPC1 4817/4885RAB9A 2989/4885HPGD 3740/4885 |
| US-20110136760-A1 | Kinase Inhibitors Useful for the Treatment of Myleoproliferative Diseases and other Proliferative Diseases | MYLK3, MYLK, CDK3 | NPC1 3414/4885RAB9A 1929/4885HPGD 2057/4885 |
| US-11065243-B2 | Inhibitors of DUX4 induction for regulation of muscle function | MUSK, MERTK, PRKDC | NPC1 4817/4885RAB9A 2989/4885HPGD 3740/4885 |
| US-20210361641-A1 | Inhibitors of DUX4 Induction for Regulation of Muscle Function | MUSK, MERTK, PRKDC | NPC1 4817/4885RAB9A 2989/4885HPGD 3740/4885 |
| US-20070078121-A1 | Enzyme modulators and treatments | ABL1, ABL2, LCK | NPC1 4813/4885RAB9A 2127/4885HPGD 1537/4885 |
| US-20080113967-A1 | ENZYME MODULATORS AND TREATMENTS | ABL2, BRAF, MAP3K1 | NPC1 4878/4885RAB9A 2892/4885HPGD 1451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.